enitociclib, a cdk9 inhibitor, for chronic lymphocytic leukemia (cll) - dr. mazyar shadman ash 2022
Published 9 months ago • 270 plays • Length 8:15Download video MP4
Download video MP3
Similar videos
-
7:45
early trial of sonrotoclax to treat chronic lymphocytic leukemia (cll) - ash 2023 dr. mazyar shadman
-
0:58
what is your preferred btk inhibitor in cll?
-
21:05
ash 2023 cll/lymphoma highlights – alpine, sequoia, swog-s1826, polarix update | dr. mazyar shadman
-
9:46
zanubrutinib for acalabrutinib-intolerant cll patients - ash 2023 mazyar shadman
-
4:10
tocilizumab treatment of covid-19
-
13:09
myeloid leukemia vaccines - creative biolabs
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
5:34
developing drug resistance after btk inhibitor therapy for cll - ash 2023 dr. mazyar shadman
-
6:45
zanubrutinib demonstrates superior pfs compared with ibrutinib for treatment of r/r cll and sll
-
1:17
dose reductions to manage aes of ibrutinib treatment for cll
-
1:54
dr. shadman on the future of venetoclax in cll
-
1:01:22
chronic lymphocytic leukemia at ash21: what's new?
-
1:05
efficacy of zanubrutinib in acalabrutinib-intolerant patients with b-cell malignancies
-
1:09
ibrutinib added to autosct conditioning and consolidation for patients with abc-dlbcl
-
0:52
tocilizumab for aa amyloidosis
-
0:57
updates on the use of zanubrutinib in wm patients intolerant to ibrutinib or acalabrutinib
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
1:36
dr. shadman on the efficacy of venetoclax in cll
-
1:34
mazyar shadman, md, on the efficacy & tolerability of zanubrutinib in b-cell malignancies